IDEA Collider: Innovation & Asymmetric Learning in Pharma

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new F...

Welcome to IDEA Collider with your host, Rick Ritacco.  In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scienti...

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.  This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA They tackle the growing view that...

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.  They take a...

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.  While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explain...

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations.  After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and...

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.    Episode Timestamps;  00:00 Welcome to Idea Collider  00:18 Kymera 2026 Catalysts  02:33...

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — and how organizations can move beyond data collection to drive smarter, more confident decision-making.  Featuring insights from Erik Nordhoy, CEO of SAI MedPartners, alongside his team, John Barry, Matt Boucher, Jennifer Preston,...

In this episode of IDEA Collider , host Mike Rea sits down with Michelle Werner , CEO of Alltrna , to explore a groundbreaking approach that could transform how we treat thousands of genetic diseases.   Michelle shares how engineered transfer RNA (tRNA) technology has the potential to address nonsense mutations — a single class of genetic errors that account for roughly 10% of genetic diseases, af...

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron and Celgene. Rick, the head of Growth and Innovation at IDEA, reminisces about the early days leading to the successful positioning and market shaping of luspatercept across different hematological indications. The episode features...

In this episode of IDEA Collider , host Mike Rea speaks with Dr. Sekar Kathiresan , founder of Verve Therapeutics and now part of Eli Lilly , about one of the boldest ideas in modern medicine: using one-time gene editing to permanently lower cholesterol and prevent heart disease . Dr. Kathiresan shares his journey from immigrant upbringing to Harvard cardiologist, genetic researcher, biotech found...

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows. The conversation dives into the impact of AI and language models on...

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Institute, through roles at Roche, to overseeing global R&D at Bayer. He shares insights on turning scientific discovery into novel medicines, collaboration between scientists and commercial teams, and the importance of maintaining s...

In this insightful episode of IDEA Collider , Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, MD PhD program at Harvard, co-founding Theravance, and leadership roles at Merck and J&J. They delve into Mathai's innovative approach to creating transformative medicines, navigating the biotech industry, and the unique challenge...

In this episode of Idea Collider , host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to leading cutting-edge biotech companies. Paul shares pivotal moments in his career, the challenges of transitioning from academia to big pharma, and the innovative principles he applied. He dives deep into Candel’s promising work...

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in Manchester and Cambridge to spearheading transformative cancer treatments at AstraZeneca. She discusses pivotal moments in her career, AstraZeneca's vision for eliminating cancer as a cause of death, the role of patient stories in...

In this episode of IDEA Collider, we dive into the world of biotech innovation with John Maraganore, former CEO of Alnylam Pharmaceuticals. Recognized as a trailblazer, John transformed RNA interference from a scientific concept into a revolutionary class of medicines, leading the development of five life-changing drugs.  Join us as we explore John's journey from a first-generation American with G...

We are excited to tell you more about the IDEA Pharma and Exploristics partnership. IDEA’s COO, Jacqui Barendregt, asked Exploristics Founder and CEO Aiden Flynn five key questions about the innovative service model and, most importantly, the value to the pharmaceutical industry this newly formed partnership will bring.

Welcome to another episode of Idea Collider with your host, Mike Rea.  In this engaging conversation, we delve into the world of pharmaceutical innovation and collaboration. Our guest, Dr. Nedim Pipic, a pharmaceutical expert specializing in mental and retinal health, shares his journey and passion for making a difference. Join us as we explore the unmet needs in these areas, the power of hybrid a...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today, Annie Duke joins us on the show to discuss her latest book, “Quit: The Power of Knowing When to Walk Away.” Annie is an Author, Professional Speaker, Decision Strategist & co-founder of The Alliance for Decision Education , a non-profit whose mission is to improve lives by empowering...

Welcome to another incredible episode of the IDEA Collider series with your host Mike Rea. Today the Chief Financial Officer at Recursion, Dr. Michael Secora, joins us on the show as we discuss the industrial revolution of drug discovery. Michael is a scientist and a former equity investor. In the episode, Michael delves into the reasons behind the incredibly fast growth at Recursion, the company’...

The healthcare industry is moving towards a digital revolution. With the help of digital technology, healthcare providers can now provide better and more efficient services to their patients. Digital technology has also proven to have a positive impact on patient outcomes, as well as the cost of care.  Companies such as Openwater , which focuses on creating the future of medical imaging, have been...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today a competitive advantage expert, and CEO of Smart Advantage, Jaynie Smith, joins us on the show.  She delves into snippets in her book, Creating Competitive Advantage, & the role of competitive advantage in increasing sales and protecting profit margins.   Moreover, she explains that it...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Sherine Khalil, the Vice President and Chief Business Officer for Valor Compounding Pharmacy . She talks about sterile and non-sterile compounding as well as her transition from the nonprofit world to academic medicine. Additionally, she delves into the major functiona...

Welcome to another incredible episode of the IDEA Collider│Pharma Book Club series with your host Mike Rea. Today we are joined by Prof. Brian D Smith, a pharma innovation geek for the past 24 years. He talks about his latest book, “ New Drugs, Fair Prices,” and how to manage the pharmaceutical innovation ecosystem for sustainable and affordable new medicines. Additionally, he delves deep into dis...